COMMUNIQUÉS West-GlobeNewswire

Sanofi obtient un avis positif du CHMP pour son vaccin contre la dengue
19/10/2018
Communiqué de presse Source : Sanofi (EURONEXT : SAN) (NYSE : SNY) Sanofi obtient un avis positif du CHMP pour son vaccin contre la dengue Paris, France - Le 19 octobre 2018 - Le Comité des médicaments à usage humain ( [...]
Integrated Cannabis Company, Inc. to Acquire Assets of Colorado-Based Cannabis Innovator, Critical Mass Industries, LLC, With an Estimated USD $7 Million in Annual Revenue
19/10/2018
VANCOUVER, British Columbia, Oct. 19, 2018 (GLOBE NEWSWIRE) -- Integrated Cannabis Company, Inc. (CSE: ICAN, OTCQB: ICNAF) (“ Integrated Cannabis ”), is pleased to announce the signing of a Letter of Intent (the “ LOI [...]
BioCorRx Strengthens Intellectual Property Portfolio with Acquisition of Several Patent/Patent Pending Families
19/10/2018
Issued patents, in addition to other intellectual property (IP) rights, cover hydrophobic drug-delivery material for BICX101 Divisional patent applications filed to strengthen BioCorRx’s intellectual property position [...]
MRI Interventions Signs Exclusive Distribution Agreement with Clinical Laserthermia Systems (CLS) for U.S. and Canada
19/10/2018
Agreement Enables MRI Interventions to Distribute CLS’s Precision Ablation Product Portfolio for Use in Interventional MR-Guided Procedures Beyond Previously Announced Spine and Neuro License Agreement IRVINE, Calif., [...]
New Studies Highlight Performance of Vectra® Test in Patients with Rheumatoid Arthritis Who Were Treated with Tofacitinib and Rituximab
19/10/2018
Data Show Vectra Test Is Correlated with Treatment Response SALT LAKE CITY, Oct. 19, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced new data from [...]
Anavex Life Sciences Announces FDA Approval of IND for Phase 2 Trial of ANAVEX®2-73 in Patients with Rett Syndrome
19/10/2018
Study will incorporate genomic precision medicine ANAVEX®2-73-specific biomarkers NEW YORK, Oct. 19, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage [...]
BeyondSpring to Host Second-Quarter 2018 Financial Results and Operational Update Conference Call on October 23, 2018
19/10/2018
Dr. Douglas Blayney from Stanford University to Join to Discuss Recently Announced Clinical Data NEW YORK, Oct. 19, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc . (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical [...]
Orion Corporation: Managers' transactions - Sydäntutkimussäätiö sr.
19/10/2018
ORION CORPORATION MANAGERS' TRANSACTIONS 19 October 2018 at 13.45 EEST Orion Corporation: Managers' transactions - Sydäntutkimussäätiö sr. Orion Corporation has received the following disclosure under Market Abuse [...]
Digirad Corporation to Release 2018 Third Quarter Financial Results on November 2, 2018
19/10/2018
Conference Call and Webcast Set for 11:00 a.m. EDT SUWANEE, Ga., Oct. 19, 2018 (GLOBE NEWSWIRE) -- Digirad Corporation (NASDAQ: DRAD) will release financial results for its third quarter ended September 30, 2018 before [...]
PCI Biotech to present Phase I dose escalation results at ESMO
19/10/2018
Oslo, Norway, 19 October 2018 — PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the company will present results from the Phase I dose escalation study in perihilar [...]
Immunicum AB (publ) Announces Nomination Committee for AGM 2019
19/10/2018
Press Release 19 October 2018 Immunicum AB (publ) Announces Nomination Committee for AGM 2019 Immunicum AB (publ) in accordance with the principles of appointing the Nomination Committee, adopted by the Annual General [...]
Rule 2.9 Announcement
19/10/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 19 October 2018 [...]
Oxurion NV Business Update - Q3 2018
19/10/2018
Shareholders' Approval and Launch of Oxurion NV as new Company Name First patient enrolled in Phase 1 study evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for Treatment of Diabetic Macular Edema (DME) First [...]
Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden
19/10/2018
Lutathera treatment was associated with an ~80% reduction in the estimated risk of tumor progression or death vs comparator, regardless of baseline liver tumor burden[1] Lutathera treatment was associated with a [...]
Kiadis Pharma raises €31.2 million in a private placement of 3.9 million new shares
19/10/2018
Not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Japan, south africa or Any other jurisdiction in which such release, publication or distribution [...]
Biocartis Group NV: Studies on Idylla(TM) MSI and RAS liquid biopsy tests to be presented at ESMO congress
19/10/2018
PRESS RELEASE : 19 October 2018, 07:00 CEST Studies on Idylla(TM) MSI and RAS liquid biopsy tests to be presented at ESMO congress Mechelen, Belgium, 19 October 2018 - Biocartis Group NV (the 'Company' or 'Biocartis'), [...]
ChemioCare Expands Proprietary Transdermal Platform
19/10/2018
DEA Registration granted: expands capability to develop controlled substances via transdermal patches NEW YORK, Oct. 18, 2018 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the “Company”), a biotech company [...]
BioTelemetry, Inc. to Release Third Quarter 2018 Earnings Results on October 30, 2018
19/10/2018
MALVERN, Pa., Oct. 18, 2018 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its third quarter 2018 earnings on Tuesday, October 30 at 4:00 PM Eastern Time. The BioTelemetry quarterly conference call [...]
Krystal Biotech Announces Pricing of $60.0 Million Public Offering of Common Stock
19/10/2018
PITTSBURGH, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech , Inc. (Nasdaq: KRYS) (the “Company”), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from [...]

Pages